Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 6
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 15
Partnerships 15
Helsinn Enters into Licensing Agreement with Chugai Pharma for Netupitant-Palonosetron Fixed-Dose Combination 15
Anaeropharma Science Enters into Research Agreement with Chugai Pharma 16
Chugai Pharma Enters into Research Agreement with National Cancer Center Japan 17
Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 18
Chugai Pharmaceutical Enters into Agreement with Osaka University 20
Chugai Pharma Enters Into Co-Development Agreement With Nippon Shinyaku For GA101 21
Licensing Agreements 22
Eli Lilly to Enter into Licensing Agreement with Chugai Pharma 22
Chugai Pharma Enters into Licensing Agreement with Roche 23
JW Pharma Enters into Licensing Agreement with Chugai Pharma 24
Chugai Pharma Enters into Licensing Agreement with SBI Pharma 25
Berlin-Chemie Enters into Licensing Agreement with Chugai Pharma 26
Galderma Pharma Enters into Licensing Agreement with Chugai Pharma 27
Roche Enters into Licensing Agreement with Chugai Pharma for Recycling Antibody SA237 28
Chugai Pharma Enters into Licensing Agreement with Two Cells 29
BioMarin Pharma Enters into Sub-license Agreement with Chugai Pharma 30
Kowa Company Enters into Licensing Agreement with Chugai Pharmaceutical 31
Roche Amends Licensing Agreement with Chugai Pharma 32
PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 33
Chugai Pharma Enters into Licensing Agreement with Roche 34
Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 35
Chugai Pharma Expands Licensing Agreement with Kowa for DEBERZA 36
Maruho Enters into Licensing Agreement with Chugai Pharma 37
EpiVax Enters into Licensing Agreement with Chugai Pharma 38
Helsinn Enters Into Licensing Agreement With Chugai Pharma Marketing For Anamorelin 39
Chugai Pharma Extends Licensing Agreement With Genedata For Genedata Expressionist Software 40
Asset Transactions 41
Taiyo Pharma to Acquire Product Rights from Chugai Pharma and Roche 41
Eisai Acquires Rights to Manufacture Active Pharmaceutical Ingredients in Japan from Chugai Pharma and F. Hoffman-La Roche 42
Acquisition 43
Roche May Acquire 40% Stake in Chugai Pharma 43
Chugai Pharmaceutical Co Ltd – Key Competitors 44
Chugai Pharmaceutical Co Ltd – Key Employees 45
Chugai Pharmaceutical Co Ltd – Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Joint Venture 49
Recent Developments 50
Strategy And Business Planning 50
Jul 27, 2018: Chugai Pharmaceutical to expand Singaporean research subsidiary 50
Jul 26, 2018: Chugai Pharmaceutical announce construction of a new synthetic research building to enhance process development for small and middle molecule APls 51
Jan 27, 2017: Aiming to Provide Solutions that Meet Changes of Regional Healthcare Services 52
Financial Announcements 53
Oct 24, 2018: Chugai Pharmaceutical: FY2018 3Q financial results 53
Corporate Communications 54
Oct 12, 2018: Chugai releases disease awareness anime about Rheumatoid Arthritis in multiple languages emphasizing importance of early detection/treatment and care by specialists 54
Jul 26, 2018: Chugai Pharmaceutical announces organizational and personnel changes 55
Dec 12, 2017: Notice on Change of Chief Executive Officer 56
Legal and Regulatory 57
Aug 29, 2018: Chugai obtains “Platinum Kurumin” certification from the minister of health, labour and welfare as a company supporting childrearing 57
Government and Public Interest 58
Mar 30, 2017: Chugai – ASTAR Joint Development Project for Anti-Dengue Virus Antibody Selected as Grant Recipient by the GHIT Fund 58
Product News 59
11/02/2017: Health Canada Approves ACTEMRA (tocilizumab) for Canadians Living with Giant Cell Arteritis 59
10/13/2017: CHMP recommends EU approval of Roche’s Alecensa (alectinib) as a first-line treatment for people with ALK-positive NSCLC 60
09/22/2017: Roche Receives European Approval for Actemra /RoActemra in Giant Cell Arteritis 61
08/30/2017: FDA approves Roche’s Actemra/RoActemra (tocilizumab) for the treatment of CAR T cell-induced cytokine release syndrome 62
08/25/2017: Approval of Actemra for Additional Indications of Takayasu Arteritis and Giant Cell Arteritis, Both are Designated Intractable Diseases 63
08/10/2017: Announcement of Commencement of Arbitration against Chugai 64
06/26/2017: Approval of Additional Dosage for “Actemra Subcutaneous Injection” Reducing Dose Interval to One Week in Patients with Rheumatoid Arthritis Who Inadequately Respond to Bi-weekly Dose 65
05/22/2017: FDA approves first drug to specifically treat giant cell arteritis 66
04/04/2017: NICE Terminates Appraisal for Alectinib in Previously Treated ALK-positive Advanced NSCLC 67
02/27/2017: Chugai’s ALK Inhibitor “Alecensa” Approved in Taiwan 68
02/21/2017: Roche receives EU approval of Alecensa (alectinib) for people with previously treated ALK-positive non-small cell lung cancer 69
Product Approvals 71
Mar 22, 2018: New Drug Application of Eldecalcitol, an Active Vitamin D3 Derivative, for the Treatment of Osteoporosis Accepted in China 71
Sep 01, 2017: Roche and MHRA to make treatment available for those newly diagnosed with a rare type of lung cancer in the UK before anywhere else in Europe 72
May 08, 2017: Roche’s Alecensa Rejects For Use Within NHS Scotland 73
Jan 23, 2017: FDA Grants Priority Review For Genentech’s Actemra (Tocilizumab) Supplemental Biologics License Application For Giant Cell Arteritis, a Form of Vasculitis 74
Clinical Trials 75
Nov 06, 2017: Eldecalcitol, an Active Vitamin D3 Derivative, Increases Bone Mineral Density of Osteoporosis Patients in Chinese Phase III Study 75
Oct 05, 2017: Chugais Bispecific Antibody ERY974 Results of Preclinical Study Published in Science Translational Medicine 76
Sep 06, 2017: Roche presents data from global phase III study showing significant clinical benefit of Alecensa (alectinib) in later-line advanced ALK-positive lung cancer 77
Aug 09, 2017: Genentech Completes Phase III Enrollment for Study of Actemra in Systemic Sclerosis 78
Aug 02, 2017: FDA Grants Genentech’s Alecensa Priority Review for Initial Treatment of People with ALK-Positive Lung Cancer 79
Jul 26, 2017: Positive Phase III Results of Genentech’s Actemra (Tocilizumab) for the Treatment of Giant Cell Arteritis Published in New England Journal of Medicine 81
Jul 25, 2017: Galderma Announces Enrollment of First Patient in Phase IIb Nemolizumab Trial in Atopic Dermatitis 83
Jul 21, 2017: Roche Gains Positive CHMP Opinion for Actemra / Roactemra in Giant Cell Arteritis 84
Jun 06, 2017: Alectinib potential new standard of care for ALK-positive non-small lung cancer 85
Jun 05, 2017: Phase III study showed Roche’s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer 86
May 11, 2017: Results of the J-ALEX Study for Chugais Alecensa are Published in The Lancet Online 88
Apr 10, 2017: Phase III study shows Roche’s Alecensa was superior to crizotinib in a specific type of lung cancer 89
Apr 03, 2017: Phase III ALUR study supports the use of Roche’s Alecensa for people with advanced ALK-positive lung cancer 90
Mar 02, 2017: Chugai’s Anti-IL-31 Receptor A Humanized Monoclonal Antibody “nemolizumab (CIM331)” Global Phase II Study Data Published in The New England Journal of Medicine Online 92
Feb 08, 2017: Roche’s Alecensa (alectinib) approved in Switzerland for people with a specific type of lung cancer 93
Other Significant Developments 95
Oct 17, 2018: F. Hoffmann-La Roche announces third quarter sales 2018 95
Oct 01, 2018: Chugai Redesigns Corporate Website 96
Apr 04, 2017: A First Approach in the Japanese Pharmaceutical Industry Starting a Trial of a Drug Adherence Support App Using Multidisciplinary SNS for Outpatient Cancer Treatment 97
Appendix 98
Methodology 98
About GlobalData 98
Contact Us 98
Disclaimer 98
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Chugai Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 10
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Helsinn Enters into Licensing Agreement with Chugai Pharma for Netupitant-Palonosetron Fixed-Dose Combination 15
Anaeropharma Science Enters into Research Agreement with Chugai Pharma 16
Chugai Pharma Enters into Research Agreement with National Cancer Center Japan 17
Astellas Pharm, Kyowa Hakko Kirin, Daiichi Sankyo, Eisai, Ono Pharma and Chugai Pharma to Enter into Agreemet with Four Research Institutions 18
Chugai Pharmaceutical Enters into Agreement with Osaka University 20
Chugai Pharma Enters Into Co-Development Agreement With Nippon Shinyaku For GA101 21
Eli Lilly to Enter into Licensing Agreement with Chugai Pharma 22
Chugai Pharma Enters into Licensing Agreement with Roche 23
JW Pharma Enters into Licensing Agreement with Chugai Pharma 24
Chugai Pharma Enters into Licensing Agreement with SBI Pharma 25
Berlin-Chemie Enters into Licensing Agreement with Chugai Pharma 26
Galderma Pharma Enters into Licensing Agreement with Chugai Pharma 27
Roche Enters into Licensing Agreement with Chugai Pharma for Recycling Antibody SA237 28
Chugai Pharma Enters into Licensing Agreement with Two Cells 29
BioMarin Pharma Enters into Sub-license Agreement with Chugai Pharma 30
Kowa Company Enters into Licensing Agreement with Chugai Pharmaceutical 31
Roche Amends Licensing Agreement with Chugai Pharma 32
PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 33
Chugai Pharma Enters into Licensing Agreement with Roche 34
Chugai Pharma Enters Into Licensing Agreement With Debiopharm Group For FF284 35
Chugai Pharma Expands Licensing Agreement with Kowa for DEBERZA 36
Maruho Enters into Licensing Agreement with Chugai Pharma 37
EpiVax Enters into Licensing Agreement with Chugai Pharma 38
Helsinn Enters Into Licensing Agreement With Chugai Pharma Marketing For Anamorelin 39
Chugai Pharma Extends Licensing Agreement With Genedata For Genedata Expressionist Software 40
Taiyo Pharma to Acquire Product Rights from Chugai Pharma and Roche 41
Eisai Acquires Rights to Manufacture Active Pharmaceutical Ingredients in Japan from Chugai Pharma and F. Hoffman-La Roche 42
Roche May Acquire 40% Stake in Chugai Pharma 43
Chugai Pharmaceutical Co Ltd, Key Competitors 44
Chugai Pharmaceutical Co Ltd, Key Employees 45
Chugai Pharmaceutical Co Ltd, Other Locations 47
Chugai Pharmaceutical Co Ltd, Subsidiaries 48
Chugai Pharmaceutical Co Ltd, Joint Venture 49
List of Figures
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10